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The treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is complex. In addition to disease control,
important therapeutic goals are themaintenance of normal growth and the acquisition of normal reproductive function. Here, data
regarding final adult height (FH) in patients with CAH will be reviewed. Additional diﬃculties associated with CAH, including
risks of obesity and hypertension, will be discussed. Information about fertility and reproductive outcomes in men and women
with CAH will also be summarized. Although the treatment of each child with CAH needs to be individualized, close medical
followup and laboratory monitoring along with good compliance can often result in positive clinical outcomes.
1. Final Adult Height in
Congenital Adrenal Hyperplasia
The pediatric endocrinologist has the diﬃcult task of
carefully adjusting medications in actively growing children
with CAH so as to avoid overtreatment as well as under-
treatment. Glucocorticoid excess may result in poor linear
growth, weight gain, hypertension, and other unwanted side
eﬀects. On the other hand, undertreatment results in excess
androgen production and advanced skeletal maturation.
An important goal in treating children with CAH is
to achieve a normal FH. Until recently, it was generally
perceived that children with CAH would ultimately be
short as adults and invariably below their genetic potential.
However, studies over the last ten years have contrasted this
idea (Table 1), suggesting that most children with CAH will
have a FH that is below their target height but within 2
standard deviations (SD) of the mean.
Studies from 1977 through 1998 [1–17] describing height
outcomes in patients with CAH were examined in a meta-
analysis with respect to FH, impact of gender, and time of
diagnosis [18]. Overall, mean weighted FH SD score (SDS)
for all studies was −1.37. In regards to gender, mean FH SDS
was −1.57 for males and −1.24 for females. When time at
diagnosis was analyzed, mean FH was−1.11 SDS for patients
identified early (less than 1 year old) as compared to −1.61
for patients indentified late (after 1 year old). Although not
all reports are in agreement, more recent studies [18–33] also
indicate that a FH within 2 SD of the mean can be achieved
with males tending to have a slightly worse outcome than
females (Table 1). Final adult height nearly equal to target
height following strict compliance and regular clinic visits
every three months has also been reported [34]. Therefore,
there is now substantial evidence that with appropriate
clinical management, most children with CAH can obtain a
FH that is within their genetic potential [18, 35].
In growing children, it is well known that an elevated
cumulative daily dose of glucocorticoids adversely aﬀects
linear growth. Glucocorticoids interfere with the normal
interactions in the growth hormone (GH)/IGF-1 signaling
cascade at the level of the hypothalamus, pituitary, and
target organ as well as adversely aﬀect hormone release,
signal and gene transduction, and mRNA processing [36].
In human studies, glucocorticoid excess causes a decrease
in GH response to growth hormone releasing hormone
(GHRH) and a paradoxical increase in IGF-1 levels [37],
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Table 1: Published reports of final height data in adults with CAH from 2001 to 2008.
First author (reference) Location Year Number at FH Mean FH SDS
Meta-analysis [1–18] Various 2001 561 −1.37 (−1.57M; −1.24 F)
Eugster et al. [18] USA 2001 23 −1.03
Hargitai et al. [19] Europe 2001 124 −1.55M; −1.25 F
Cabrera et al. [20] USA 2001 30 −1.65M
Manoli et al. [21] Greece 2002 48
−0.57M (SW); −0.61 F (SW); −1.05M (SV);
−1.4 F (SV); +0.3 F (NC)
Muirhead et al. [22] Canada 2002 54 −1.4M; −1.1 F
Van der Kamp et al. [23] Netherlands 2002 53 −1.27M (SW); −1.25 F (SW); −1.51M (SV); −0.96 F (SV)
Pinto et al. [24] France 2003 27 −2.0 (SW, SV); −1.2 (NC)
Balsamo et al. [25] Italy 2003 55 −0.95 (SW); −1.36 (SV); −0.85 (NC)
Brunelli et al. [26] Italy 2003 93 −1.3 (SW); −1.8 (SV); −1.7 (NC)
Grigorescu-Sido et al. [27] Romania 2003 17 −1.49
Tung et al. [28] Taiwan 2005 44 −1.4M; −1.2 F
Lemos-Marini et al. [29] Brazil 2005 27 −1.57
Aycan et al. [30] Turkey 2006 5 −1.77
Sciannamblo et al. [31] Italy 2006 30 −1.71M; −1.06 F
Bonfig et al. [32] Germany 2007 125 −1.0M (SW); −0.8 F (SW); −1.4M (SV); −1.3 F (SV)
Chakhtoura et al. [33] France 2008 38 −0.94 (−1.35M; −0.80 F)
Hoepﬀner et al. [34] Germany 2008 39 −1.2a∗; +0.1b∗
FH= final height; SDS= standard deviation score; M=male; F= female; SW= salt-wasting; SV= simple-virilizing; NC= non-classic; apatients born before
1975 (n = 13); bpatients born from 1975 to 1986 (n = 26); ∗value is corrected FH SDS (or FH SDS—target height SDS).
creating a state of GH resistance. Although IGF-1 levels
are elevated, studies in rats have shown that serum free
IGF-1 levels are decreased after high-dose glucocorticoid
administration [38]. In other animal studies, glucocorticoids
decrease GH receptor synthesis and GH-induced IGF-1
mRNA expression [39]. Glucocorticoids also disturb normal
calcium balance in the intestine and kidney and can interfere
with osteoclast, osteoblast, and chondrocyte interaction [36].
In animal studies, glucocorticoids also induce apoptosis of
chondrocytes through activation of caspases and inhibit
the phosphatidylinositol 3′-kinase (PI3K) signaling pathway
[40]. Thus, the negative impact of excess glucocorticoids on
growth occurs through multiple diﬀerent mechanisms. In
general, hydrocortisone given three times a day has been
associated with optimal outcomes [32]. Other forms of
glucocorticoids, including prednisone and dexamethasone,
have also been studied and are discussed in other sections
of this supplement.
Higher doses of glucocorticoids in children with CAH
result in decreased linear growth. In a prospective trial
of 26 children with classic CAH, subjects were random-
ized to 15mg/m2/day or 25mg/m2/day of hydrocortisone
for six months and then crossed-over to the other dose
[41]. Hydrocortisone was administered in three divided
doses, and fludrocortisone was also given daily. Height
velocity was significantly decreased during treatment with
25mg/m2/day as compared with 15mg/m2/day. A decrease
in growth velocity was the most sensitive clinical indicator
of glucocorticoid excess, and height velocity positively cor-
related with 17-hydroxyprogesterone concentrations [41].
The authors found that optimal growth occurred at an
average plasma 17-hydroxyprogesterone concentration of
21 nmol/L (or 695 ng/dL). Thus, overzealous administration
of glucocorticoids must be avoided.
2. Growth during Critical Periods—Impact of
Glucocorticoids and Androgen Exposure
during Infancy and Puberty
Birth length in individuals with CAH was found in two
reports to be significantly increased when compared to
unaﬀected newborns [15, 42]. In one study [15], birth
length of boys and girls diagnosed with CAH in infancy was
statistically greater than the national mean birth lengths in
Finland. In another study [42], the average birth length in
boys (51.2 ± 1.7 cm) and girls (50.3 ± 1.5 cm) with classic
CAH was significantly greater than the mean birth length
of unaﬀected Italian boys (50.7 ± 2.0 cm) and girls (49.4 ±
2.0 cm). Interestingly, the mean birth length in children with
non-classic CAH did not diﬀer significantly from the average
birth length of Italian children [42]. These reports suggest
that in utero hyperandrogenism can aﬀect prenatal growth in
severely aﬀected children. Other studies have reported birth
lengths in children with CAH that were mostly within the
normal range [43].
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Infancy is a critically important time of growth and
development. As is true in older children, impaired linear
growth during infancy often reflects excess glucocorticoid
therapy. In an Italian study [25], children with CAH who
received a lower equivalent dose of hydrocortisone during
the first year of life reached a better FH than those who
received a higher dose. In particular, a negative influence
on linear growth and ultimate height has been observed
at hydrocortisone doses of more than 20 to 25mg/m2/day
during infancy [14, 22, 44]. In a retrospective study from
the Netherlands of 48 patients with salt-wasting CAH
[45], a negative relationship between mean daily gluco-
corticoid dose during the first year of life and FH was
noted.
Interestingly, the negative eﬀect of androgen excess on
growth and skeletal maturation seen in later childhood does
not occur during infancy. In a report from Sweden [46],
children with a delayed diagnosis of CAH or who were
undertreated early in life did not have growth acceleration
or virilization until after 18 months of life, suggesting that
growth prior to this time is insensitive to androgen exposure.
In a study from the Netherlands [43], the growth pattern and
skeletal maturation of 17 children with untreated simple-
virilizing CAH revealed no increased height velocity in
the first 12 months of life, which also suggests a relative
resistance to androgen excess during infancy. However, after
this time period, there was a progressive increase in growth
velocity and bone maturation corresponding to the degree
and duration of androgen exposure [43].
Another critically important time of growth in all
children is early adolescence and puberty. In children with
CAH, several studies have found impaired linear growth
during puberty [19, 21–23, 32, 45]. After the age of 12
months and before 8 years, Stikkelbroeck et al. found no
significant eﬀect of glucocorticoid dose on height SDS [45].
However, between the ages of 8 and 14 years, there was a
dose-dependent negative eﬀect of glucocorticoids on linear
growth. In other reports, the peak pubertal growth spurt
occurred approximately 2 years earlier and the magnitude
of the peak height velocity was lower in children with
CAH when compared to controls [19, 47]. In a study
comparing individuals treated with prednisone versus hydro-
cortisone, total pubertal growth was significantly decreased
in both groups, and treatment with prednisone resulted in
a decreased FH [32]. The dose at the start of puberty in
the hydrocortisone-treated group was 16.7 ± 4.1mg/m2/day
versus 21.0± 8.1mg/m2/day in the prednisone-treated group
using a relative glucocorticoid potency conversion of one for
hydrocortisone and four for prednisone. The hydrocortisone
equivalent dose at the onset of puberty correlated negatively
with FH. In further analysis, the authors suggested that the
deleterious eﬀects on pubertal growth can be reduced if the
hydrocortisone dose does not exceed 17mg/m2/day [48].
Overtreatment of CAH at the onset of puberty may result in
a less profound growth spurt due to an attenuated influence
of sex steroids on growth [32]. Furthermore, inhibition of
pituitary GH secretion during puberty may occur due to
increased hypothalamic somatostatin release as a result of
glucocorticoid excess [49, 50].
Eﬀorts to improve FH in children and adolescents
with CAH have led researchers to investigate alterna-
tive and experimental adjunctive therapies, such as GH,
gonadotropin-releasing hormone (GnRH) agonists, aro-
matase inhibitors, androgen blockers, or a combination of
these medications. In a study from the United States [51],
12 children with CAH received GH and 8 received GH plus
a GnRH analog. In both groups, growth rate and height
prediction improved and there was a reduction in height
deficit for bone age after one and two years of therapy
[51, 52]. In a nonrandomized study of 14 patients with
CAH who received both GH and a GnRH analog, FH and
gain in height were statistically better when compared to
a similar, untreated group [53]. Mean FH SDS was −0.4
± 0.8 in the treated group compared to −1.4 ± 1.1 in
the untreated group. A diﬀerent treatment strategy has
used an antiandrogen (flutamide), an aromatase inhibitor
(testolactone or letrozole), and a reduced hydrocortisone
dose (less than 9mg/m2/day) in children with CAH [54,
55]. In a randomized, cross-over short-term pilot study of
12 children using this experimental regimen compared to
traditional hydrocortisone therapy, improved outcomes in
linear growth, weight gain, and skeletal maturation were
observed [54]. Two-year followup data were later published
showing no adverse events and promising results despite
elevated androgen levels in those on the experimental
therapy [55]. Final height data and long-term safety results
from this cohort of children have not yet been published.
3. Mineralocorticoid and Salt
Replacement—Important Influences on
Growth and Height Outcome
Besides glucocorticoids, mineralocorticoid and salt replace-
ment in children with CAH also play an important role
in linear growth. Mineralocorticoid therapy with fludrocor-
tisone normalizes plasma renin activity and salt balance.
Studies have shown that mineralocorticoid therapy in salt-
wasting CAH improves linear growth and may allow for
lower doses of glucocorticoids [56]. In a German study [34],
a retrospective analysis of 39 adult patients with CAH found
that a reduced daily dose of glucocorticoid was possible
with the addition of daily fludrocortisone and was associated
with improved FH. The authors proposed using a daily
fludrocortisone dose of 110mcg/m2 from preschool age
onwards and suggested that this would result in a reduced
mean hydrocortisone dose of approximately 13mg/m2/day
in their patients. In a study from Italy [25], CAH patients
treated early (before 3 years of age) with mineralocorticoid
had an improved FH as compared to those treated late (after
5 years of age) or never. Final adult height in those treated
early was 158.2 ± 5.6 cm (−0.66 ± 0.98 SDS) compared to
153.6 ± 4.8 cm (−1.49 ± 0.79 SDS) in those treated late
(P < .05).
Salt supplementation during the first year of life has
also been associated with improved linear growth and FH.
In 34 patients from the Netherlands [23], half received
supplemental salt at a dose of 2.5 ± 3.0mmol/kg/day
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(or approximately 150mg/kg/day) from 0.19 ± 0.15 years
until 0.9 ± 0.38 years, and all received a similar dose of
fludrocortisone. Mean length SDS at 2 years of life was higher
in the salt supplemented group (−1.0 SDS) versus the group
without salt supplementation (−1.56 SDS). Furthermore,
FH corrected for target height was significantly higher in
the salt supplemented group (−0.83 SDS) compared to the
nonsupplemented group (−1.69 SDS) (P < .003). The
authors also found a positive correlation between FH SDS
and salt supplementation during the first year of life.
Complete aldosterone deficiency occurs in individuals
with the most severe CYP21 gene mutations resulting in salt-
wasting CAH. However, a study by Nimkarn et al. [57] has
shown that there is some degree of aldosterone deficiency
present in all forms of 21-hydroxylase deficiency, including
simple-virilizing and non-classic forms. In an analysis of
402 individuals, the aldosterone to plasma renin activity
ratio was abnormal in all forms of 21-hydroxylase deficiency,
suggesting a spectrum of salt loss in CAH. Since salt-wasting
crises do not occur in individuals with non-classic CAH,
mineralocorticoid replacement is not required. Additional
research is needed to see if mineralocorticoid replacement
may benefit FH in all forms of CAH.
4. Other Complications—Weight Gain
and Hypertension
Children with CAH are at an increased risk of developing
obesity [58, 59]. Glucocorticoid dosage, chronological age,
advanced skeletal maturation, and parental obesity were
associated with an elevated body mass index (BMI) and
obesity in a cross-sectional study of 89 children with CAH
from Germany [59]. It is generally believed that excess
glucocorticoid treatment in children with CAH results in
weight gain and iatrogenic Cushing syndrome.
Another complication, which may or may not be related
to weight gain or medications in the treatment of CAH, is
hypertension [60]. Although hypertension is commonly dis-
cussed in the context of 11-beta-hydroxylase and 17-alpha-
hydroxylase deficiencies due to elevated adrenal hormone
metabolites with mineralocorticoid activity, it is not typically
considered to be a component of 21-hydroxylase deficiency.
Iatrogenic hypertension can occur from excess administra-
tion of medications with mineralocorticoid activity [61, 62].
Despite a reduction in the dose of fludrocortisone as well as
a decrease in the dose of glucocorticoid, hypertension may
persist in some individuals with CAH [62].
There are a few reports describing 24-hour ambulatory
blood pressure monitoring in children and adolescents with
CAH [63–66]. In a study by Roche et al. [63], 84% of
children with salt-wasting CAH had absence of the normal
physiologic nocturnal dip in systolic blood pressure. Blood
pressure measurements were not correlated with any bio-
chemical markers of CAH control. However, hypertension
was strongly associated with obesity, particularly in females
[63]. In another study, long-term glucocorticoid therapy did
not correlate with blood pressure values [64]. In a report of
55 subjects with CAH in Germany [65], abnormal 24-hour
blood pressure profiles and systolic hypertension correlated
with the degree of overweight and obesity. Researchers
found elevated serum leptin and insulin levels, which closely
correlated to BMI and age, but laboratory markers of CAH
control, glucocorticoid dose, and fludrocortisone dose did
not correlate with blood pressure [65]. In another report
of 23 children and adolescents with CAH, average blood
pressure values were noted to be in the upper normal range
[66].
As children with CAH are prone to increased weight
gain and obesity, we examined our own population of
CAH patients to see if an elevated BMI was a predictive
factor in the development of hypertension [67]. Ninety-
one patients with 21-hydroxylase deficiency were identified.
Six (6.6%) were found to have hypertension. One child
developed hypertension after presenting in an adrenal crisis
with rhabdomyolysis and acute renal failure. Therefore,
5 children (5.5%) had essential hypertension, which was
defined as hypertension of unknown etiology after an
extensive evaluation by a pediatric cardiologist and pediatric
nephrologist. Family history for hypertension was negative
in all subjects who had essential hypertension. The age
at diagnosis of hypertension ranged between 2 months
to 12.6 years. All 5 children required anti-hypertensive
medications, and only one child was able to eventually
stop anti-hypertensive medication after 7 years of therapy.
None of the subjects had a suppressed plasma renin activity
at the time of diagnosis of hypertension, which implies
that mineralocorticoid replacement was not excessive. The
average dose of fludrocortisone at the time of diagnosis
of hypertension was 0.09 ± 0.05mg/day. Also, the aver-
age dose of hydrocortisone at the time of diagnosis of
hypertension was 16.4 ± 1.6mg/m2/day, which suggests that
excess glucocorticoid administration was not the culprit.
Interestingly, an elevated BMI was not a determining factor
in the development of hypertension. The average BMI was
not statistically diﬀerent between those without hypertension
(23.9± 9.1) as compared to those with essential hypertension
(22.9 ± 2.9) [67]. The exact mechanism to explain why
some individuals with CAH due to 21-hydroxylase deficiency
develop hypertension is unclear, and further investigation is
warranted.
5. Reproductive Outcome—Men
Compared to the general adult male population, men with
CAH have reduced fertility [68]. While some males with
CAH may develop hypogonadotropic hypogonadism due to
high levels of sex steroids which suppress the hypothalamic-
pituitary-gonadal axis, the most common reason for reduced
fertility in men with CAH is the presence of testicular
adrenal rest tumors (TARTs) [68, 69]. TARTs are usually not
noticed by the patient or physician on physical exam unless
they are greater than 2 cm [69]. Although most TARTs are
nonpalpable, the majority of adolescent and adult males with
CAH have one or more tumors. In a study of 17 adolescent
and adult males with CAH [70], 6 individuals had palpable
TARTs. In the remaining 11 patients, 10 had nonpalpable
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Table 2: Proposed five stage classification of TARTs (modified from [69, 79]).
Stage Histological description Testicular ultrasound Reversibility Treatment options






Proliferation of adrenal rest cells
due to growth-promoting factors
(such as Angiotensin II and ACTH)
May become visible as one or more
small hypoechogenic lesions
+++ Increase dose and intensify
glucocorticoid therapy
3
Growth of adrenal rest cells leads to
compression of the rete testis,
obstruction of the seminiferous
tubules, and evidence of gonadal
dysfunction (↑ FSH, ↑ LH, ↓ sperm,
↓ inhibin B)
Detectable ++
Increase dose and intensify




hyperplasia of adrenal rest cells with
progressive obstruction of rete testis
with fibrosis within the tumor and
focal lymphocytic infiltration
Detectable—small tumors may
form a single lobulated structure
−/+ Consider surgery but may not
reverse testicular damage.
5
Chronic obstruction leads to
destruction of surrounding
testicular parenchyma
Detectable − None—irreversible damage.
TARTs which were visible only by ultrasound. In the 11
patients who had semen analysis, abnormalities were noted
in 7, and the best result was from the patient without any
evidence of TART. In another study [20], 18 adult males with
CAH had testicular ultrasounds and half were found to have
TARTs. In the 9 aﬀected patients, 7 had semen analysis and
all were infertile. In a German study [71], 19 of 22 adult male
patients with CAH were found to have an abnormal semen
analysis and most were infertile.
TARTs are typically found in the rete testis, and more
than 80% of patients have bilateral disease [69]. Due to
their central location, TARTs can compress the seminifer-
ous tubules and cause end-stage damage of the testicular
parenchyma [72]. Testicular biopsies of 7 male patients with
long-standing TARTs revealed decreased spermatogenesis
and decreased tubular diameter with peritubular fibrosis
[72]. There is no evidence that TARTs are malignant [68,
69]. However, long-standing TARTs can lead to irreversible
testicular damage, and early recognition and treatment may
prevent fertility problems [69, 72].
TARTs produce adrenal-specific steroids, contain
adrenal-specific enzymes, and express ACTH and
angiotensin II receptors [73]. Therefore, the first-line
of treatment in a patient with a TART is to increase the
glucocorticoid dose, which leads to suppression of ACTH
secretion and may result in a decrease in size of the tumor
and improvement in semen quality and fertility [74, 75].
In large, long-standing TARTs, increasing the dose of
glucocorticoid may not be eﬀective but removal of the
tumor may prevent further testicular damage [69]. However,
testis-sparing surgery may not improve gonadal function if
permanent testicular damage has already occurred. In a study
of 8 male CAH patients with bilateral TARTs and infertility
[76], pituitary-gonadal testing and semen analysis was
performed before and 6 and 22 months after testis-sparing
surgery. Pituitary-gonadal function and semen analysis did
not improve after surgery. Furthermore, all patients had
persistently low inhibin B levels, indicating reduced Sertoli
cell function. Although patients were followed for less than 2
years after surgery, these results suggest that testicular dam-
age from TARTs may be irreversible if detected at a late stage.
Although most reports have investigated the prevalence
of TARTs in adolescent and adult males with CAH, tumors
have also been discovered in prepubertal males [77, 78].
In a study from the Netherlands [77], scrotal ultrasound
was performed in 34 children with CAH between the
ages of 2 and 18 years. TARTs were detected in 24% of
children and most commonly in those with salt-wasting
CAH. The youngest child noted to have TARTs was 7.25
years [77]. Markers of gonadal function, including LH, FSH,
testosterone, and inhibin B levels, in children with and
without TARTs was similar. In a diﬀerent report from Chile
[78], 19 children were studied between the ages of 2 and 10
years. TARTs were detected by ultrasound in 21%, and all had
salt-wasting CAH. TARTs were detected in children aged 6.8,
7.3, 8.5, and 9.6 years. However, unlike the former study [77],
markers of Sertoli and Leydig cell function were reduced,
especially in those with elevated androgen levels indicating
inadequate control of CAH [78].
Based upon the histological appearance and clinical
observations of TARTs, including natural history and avail-
able treatment options, a five stage classification of TARTs
(Table 2) has recently been proposed by a group from the
Netherlands with extensive clinical experience [69, 79].
6. Reproductive Outcome—Women
When compared to unaﬀected women, adult women with
CAH have decreased fertility rates [80–87]. The most widely
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recognized cause of low fertility rates in women with CAH
is suboptimal disease control [88]. With adequate gluco-
corticoid and mineralocorticoid replacement, many sexually
active women with CAH can become pregnant [89]. Even
when the diagnosis of CAH is delayed and glucocorticoid
replacement is not started until after age 9 years, chronic
androgen exposure does not permanently or adversely
aﬀect fertility [90]. Other factors which may contribute to
decreased fertility rates include ovarian hyperandrogenism
and polycystic ovarian syndrome, complications related to
genital surgery, and psychological factors [68].
In a review of pregnancy outcomes from 1956 through
2000 [82], 73 women with virilizing CAH had a total of
105 pregnancies. Women with the most severe, salt-wasting
forms have the lowest fertility rates [82, 86]. Sexual function
is reduced in women with CAH compared to controls, and
it is lowest in women with the most severe degrees of
virilization. In a study from France [85], 81% of women
with CAH reported pain during vaginal penetration, and
half were noted to have moderate or severe stenosis of their
introitus. The live-birth rate in classic salt-wasting forms
has been reported to be 0% to 10%, in simple virilizing
forms 33% to 50%, and in non-classic forms 63% to 90%
[84]. In a review by Lo and Grumbach [82], approximately
10% of pregnancies were spontaneously aborted and 10%
had therapeutic abortions. Other reports have found a
termination rate of approximately 6% [87]. The elective
abortion rate of up to 10% may be due to women with
CAH believing that their chance of becoming pregnant was
impossible.
More recent studies have suggested improved pregnancy
outcomes, which may be due to more stringent medical
management with steroid replacement. In a report of 106
women with CAH from the United Kingdom [87], 21 of 23
trying to conceive achieved 34 pregnancies, which calculates
to a pregnancy rate of 91.3% which is similar to the normal
population (95%). However, the overall fertility rate was
significantly lower than in the general population (0.25
versus 1.8). In those women who are able to conceive,
pregnancy is generally uneventful [83, 91], although there is
a higher incidence of delivery by cesarean section [91].
Unlike in males with CAH, adrenal rest tumors in the
ovaries of females with CAH are extremely rare and therefore
not a significant cause of decreased fertility [68]. There have
been only 3 reports of females with CAH who were found
to have ovarian adrenal rest tissue [92–94]. In a study of 13
adolescent and adult females with CAH, none were found to
have ovarian adrenal rest tumors by ultrasound or magnetic
resonance imaging [95].
Girls born to women with CAH are generally unaﬀected
and have normal external genitalia since the placenta serves
as a metabolic barrier to reduce fetal exposure to maternal
androgens through placental aromatization of maternal
testosterone and androstenedione [96]. There have been
two reports of female infants born to mothers with CAH
who had mild external virilization [97, 98]. In the first
case, the infant was noted to have clitoral enlargement with
normal vaginal and urethral openings and no labioscrotal
fusion [97]. The other infant only had rugose labia majora
with no clitoromegaly and a normal introitus [98]. To our
knowledge, there has been only one reported case of amother
with classic, salt-wasting CAH having a female child with
the same disorder [99]. Although not published, we are also
aware of a male child at our institution with severe, salt-
wasting CAH whose mother also had the same condition.
Even though fertility is decreased, it is important to provide
genetic counseling for adolescent and adult women with
CAH. In addition, contraception counseling should also
be considered with sexually active women with CAH since
fertility is possible, especially in those women with good
disease control.
7. Conclusion
With strict compliance to medical therapy as well as close
clinical and laboratory monitoring, men and women with
CAH can achieve a normal FH that is close to their calculated
target height. Critical periods of growth when overtreat-
ment with glucocorticoids should especially be avoided are
during infancy and puberty. Replacement with salt and
mineralocorticoid is also important in optimizing the linear
growth of children with CAH. Side eﬀects, which may or
may not be related to glucocorticoid and mineralocorticoid
replacement, include weight gain and hypertension. Fertility
in men and women with CAH is reduced. In men, TARTs
are the major cause of decreased fertility and early detection
may help to reduce the risk of infertility. In women, fertility
and reproductive outcome can be enhanced with improved
biochemical control of CAH. Ongoing investigation of new
therapies and novel strategies for clinical management will
continue to enhance long-term growth and reproductive
outcomes in individuals with CAH.
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